LONG-TERM OUTCOMES OF RETINAL DEGENERATIVE DISORDER TREATMENT WITH PEPTIDE BIOREGULATORS
Aim. To analyze long-term outcomes and efficacy of retinal degeneration treatment with Retinalamin.
Patients and methods. Group I included 20 patients (40 eyes) with pigmentary retinal dystrophy (15 patients, 30 eyes) and retinal abiotrophy (5 patients, 10 eyes) who received treatment with Retinalamin for 5‑7 years. Group II included 11 patients (22 eyes) with pigmentary retinal dystrophy (9 patients, 18 eyes) and retinal abiotrophy (2 patients, 4 eyes) who received treatment with Retinalamin for 23‑25 years. Group III (controls) included 15 patients (30 eyes) with pigmentary retinal dystrophy (11 patients, 22 eyes) and retinal abiotrophy (4 patients, 8 eyes) who received traditional treatment (vasodilators, angioprotectors, antisclerotic agents, vitamins) for 25 years. Standard ophthalmological examination, i.e., visual acuity measurement, visual field test, refractometry, biomicroscopy, ophthalmoscopy, was performed.
Results. First course of treatment with Retinalamin improved vision in 58.1 % of retinal degeneration patients. Visual fields improved in 64.5 % of cases. Repeated treatment courses (1‑2 times a year) for 23‑25 years preserved residual vision in 55.6 % of patients and object vision in 11.1 % of cases. In retinal abiotrophy patients, residual vision preserved in 100 % of cases.
Conclusions. In retinal degenerations, Retinalamin improves vision and visual fields and decreases total area of absolute scotomas even after the first treatment course as well as preserves vision in prolonged use.
Document Type: Research Article
Affiliations: Санкт-Петербургский научно-практический центр медико-социальной экспертизы, протезирования и реабилитации инвалидов им. Г. А . Альбрехта
Publication date: January 1, 2015